TY - JOUR
T1 - The short-term effects of antioxidant and zinc supplements on oxidative stress biomarker levels in plasma
T2 - A pilot investigation
AU - Brantley, Milam A.
AU - Osborn, Melissa P.
AU - Sanders, Barton J.
AU - Rezaei, Kasra A.
AU - Lu, Pengcheng
AU - Li, Chun
AU - Milne, Ginger L.
AU - Cai, Jiyang
AU - Sternberg, Paul
N1 - Funding Information:
All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest, and none were reported. Publication of this article was supported by Grants EY007892 (P.S.), P30 EY08126 , P30 ES000267 (G.L.M.), and CTSA grant 1 UL1 RR024975 from the National Institutes of Health , Bethesda, Maryland; the Jahnigen Career Development Award from the American Geriatrics Society, New York, New York (M.A.B.); the Carl M. & Mildred A. Reeves Foundation, Columbus, Indiana (M.A.B.); and an unrestricted departmental grant from Research to Prevent Blindness Inc , New York, New York. Involved in study design and conduct (M.A.B., J.C., P.S.); data collection (B.J.S., K.A.R., G.L.M., J.C.); data management, analysis, and interpretation (M.A.B., M.P.O., P.L., C.L., G.L.M., J.C., P.S.); manuscript preparation (M.A.B., M.P.O., P.S.); and manuscript review and approval (M.A.B., M.P.O., B.J.S., K.A.R., P.L., C.L., G.L.M., J.C., P.S.). All procedures were approved prospectively by the local Institutional Review Board, the Vanderbilt University Human Research Protection Program. Research adhered to the tenets of the Declaration of Helsinki and was conducted in accordance with Health Insurance Portability and Accountability Act regulations. Informed consent was obtained from all participants upon study enrollment. The NCT Registry Number for this clinical trial is NCT00668213 . The authors would like to thank the staff of the Eicosanoid Core Laboratory for the measurements of isoprostanes and isofurans, Cindy Dossett for designing controlled meal plans, and the staff of the Vanderbilt General Clinical Research Center.
PY - 2012/6
Y1 - 2012/6
N2 - Purpose: To determine if short-term Age-Related Eye Disease Study (AREDS) antioxidant and zinc supplementation affects biomarkers of oxidative stress, possibly serving as a predictor of their efficacy. Design: Prospective interventional case series. Methods: Nineteen subjects, 12 with intermediate or advanced age-related macular degeneration (AMD) (AREDS categories 3 or 4) and 7 non-AMD controls, were admitted to the Vanderbilt General Clinical Research Center and placed on a controlled diet for 7 days. Antioxidant and zinc supplements were stopped 2 weeks prior to study enrollment. Dietary supplementation with 500 mg vitamin C, 400 IU vitamin E, 15 mg β-carotene, 80 mg zinc oxide, and 2 mg cupric oxide per day was instituted on study day 2. Blood was drawn on study days 2 and 7, and plasma concentrations of cysteine (Cys), cystine (CySS), glutathione (GSH), isoprostane (IsoP), and isofuran (IsoF) were determined. Results: Short-term AREDS supplementation significantly lowered mean plasma levels of CySS in participants on a regulated diet (P =.034). No significant differences were observed for Cys, GSH, IsoP, or IsoF. There were no significant differences between AMD patients and controls. Conclusions: This pilot interventional study shows that a 5-day course of antioxidant and zinc supplements can modify plasma levels of CySS, suggesting that this oxidative stress biomarker could help predict how likely an individual is to benefit from AREDS supplementation. Further, CySS may be useful for the evaluation of new AMD therapies, particularly those hypothesized to affect redox status.
AB - Purpose: To determine if short-term Age-Related Eye Disease Study (AREDS) antioxidant and zinc supplementation affects biomarkers of oxidative stress, possibly serving as a predictor of their efficacy. Design: Prospective interventional case series. Methods: Nineteen subjects, 12 with intermediate or advanced age-related macular degeneration (AMD) (AREDS categories 3 or 4) and 7 non-AMD controls, were admitted to the Vanderbilt General Clinical Research Center and placed on a controlled diet for 7 days. Antioxidant and zinc supplements were stopped 2 weeks prior to study enrollment. Dietary supplementation with 500 mg vitamin C, 400 IU vitamin E, 15 mg β-carotene, 80 mg zinc oxide, and 2 mg cupric oxide per day was instituted on study day 2. Blood was drawn on study days 2 and 7, and plasma concentrations of cysteine (Cys), cystine (CySS), glutathione (GSH), isoprostane (IsoP), and isofuran (IsoF) were determined. Results: Short-term AREDS supplementation significantly lowered mean plasma levels of CySS in participants on a regulated diet (P =.034). No significant differences were observed for Cys, GSH, IsoP, or IsoF. There were no significant differences between AMD patients and controls. Conclusions: This pilot interventional study shows that a 5-day course of antioxidant and zinc supplements can modify plasma levels of CySS, suggesting that this oxidative stress biomarker could help predict how likely an individual is to benefit from AREDS supplementation. Further, CySS may be useful for the evaluation of new AMD therapies, particularly those hypothesized to affect redox status.
UR - http://www.scopus.com/inward/record.url?scp=84862806474&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862806474&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2011.12.010
DO - 10.1016/j.ajo.2011.12.010
M3 - Article
C2 - 22381365
AN - SCOPUS:84862806474
SN - 0002-9394
VL - 153
SP - 1104-1109.e2
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
IS - 6
ER -